Transcode Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
RNAZ$1.54+3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURE
SIGNA****TURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TRANSCODE THERAPEUTICS, INC. | |
| Date: May 15, 2026 | /s/ Philippe P. Calais |
|---|---|
| Philippe P. Calais | |
| Chief Executive Officer | |
| (Principal Executive Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.